logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10316361 B1

PDFFull Text
Date of Patent:
Jun. 11, 2019

Filed:

Jul. 16, 2012

Genome-wide methylation analysis and use to identify genes specific to breast cancer hormone receptor status and risk of recurrence

Applicants:

Saraswati V. Sukumar, Columbia, MD (US);

Christopher Benedict Umbricht, Towson, MD (US);

Antonio C. Wolff, Baltimore, MD (US);

Mary JO Steele Fackler, Hunt Valley, MD (US);

Zhe Zhang, Columbia, MD (US);

Leslie M. Cope, Baltimore, MD (US);

Kala Visvanathan, Baltimore, MD (US);

Peng Huang, Owings Mills, MD (US);

Inventors:

Saraswati V. Sukumar, Columbia, MD (US);

Christopher Benedict Umbricht, Towson, MD (US);

Antonio C. Wolff, Baltimore, MD (US);

Mary Jo Steele Fackler, Hunt Valley, MD (US);

Zhe Zhang, Columbia, MD (US);

Leslie M. Cope, Baltimore, MD (US);

Kala Visvanathan, Baltimore, MD (US);

Peng Huang, Owings Mills, MD (US);

Assignee:

THE JOHN HOPKINS UNIVERSITY, Baltimore, MD (US);

Attorney:

John Hopkins Technology Ventures

Primary Examiner:

Stephen T Kapushoc

Int. Cl.
CPC ...
C12P 19/34 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6874 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01);
Abstract

To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.

Find Patent Forward Citations

Sukumar, Saraswati. (2019). Genome-wide methylation analysis and use to identify genes specific to breast cancer hormone receptor status and risk of recurrence (U.S. Patent No. 10316361). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10316361

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…